Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Eur J Surg Oncol. 2022 Aug;48(8):1723-1729. doi: 10.1016/j.ejso.2022.01.003. Epub 2022 Jan 21.
this study analysed primary myxofibrosarcoma (MFS) to investigate patient outcomes focusing on histopathologic margins and perioperative treatments.
data from consecutive patients affected by primary and localized MFS of the extremities or trunk wall who underwent surgery (2002-2017) were analysed. Local recurrence (LR), amputation rate, incidence of distant metastasis (DM), and overall survival (OS) were studied.
Of 293 included patients, 52 (17%) patients received perioperative treatments and 54 (18%) had positive microscopic histopathologic margins (R1). Median follow-up was 80 months (IQR, 49-109). 5-yr CCI of LR was 0.12 (SE: 0.02). Status of histopathologic margins (P < 0.001), tumour malignancy grade (P = 0.018) and size (P = 0023) were independent prognostic factor for LR. Nine amputations (amputation rate: 3%) were performed (N = 1 for primary tumour; N = 8 for LR). Larger tumour size (P = 0.015) and higher grade (P = 0.025) were independent prognostic factor for DM. 5-year OS was 0.84 (95%CI 0.79-0.88). Patient age (P = 0.008), tumour size (P = 0.013) and malignancy grade (P = 0.018) were independently associated to OS. In the subgroup of patients who had a re-excision for a primary MFS (N = 116, 40%), the presence of residual disease was not associated with LR, DM, or OS.
in this study 5-year LR, DM and OS were 12%, 17%, and 84%, respectively. One in six patients had a positive surgical margin, which was a prognostic factor for LR, while DM and OS were predicted by tumour grade and size. Findings from this large patient cohort may set benchmarks for investigating new treatment options for MFS.
本研究分析了原发性黏液纤维肉瘤(MFS),重点关注组织病理学切缘和围手术期治疗,以研究患者的结局。
分析了 2002 年至 2017 年间连续接受手术治疗的局限性原发性四肢和躯干壁 MFS 患者的数据。研究了局部复发(LR)、截肢率、远处转移(DM)发生率和总生存率(OS)。
在 293 名纳入患者中,52 名(17%)患者接受了围手术期治疗,54 名(18%)患者的组织病理学切缘呈阳性(R1)。中位随访时间为 80 个月(IQR,49-109)。LR 的 5 年 CCI 为 0.12(SE:0.02)。组织病理学切缘状态(P < 0.001)、肿瘤恶性程度分级(P = 0.018)和肿瘤大小(P = 0.023)是 LR 的独立预后因素。9 例患者行截肢术(截肢率:3%)(N = 1 例为原发性肿瘤;N = 8 例为 LR)。肿瘤体积较大(P = 0.015)和恶性程度较高(P = 0.025)是 DM 的独立预后因素。5 年 OS 为 0.84(95%CI 0.79-0.88)。患者年龄(P = 0.008)、肿瘤大小(P = 0.013)和恶性程度分级(P = 0.018)与 OS 独立相关。在原发性 MFS 再次切除术的患者亚组(N = 116,40%)中,残留疾病的存在与 LR、DM 或 OS 无关。
在本研究中,5 年 LR、DM 和 OS 分别为 12%、17%和 84%。1/6 的患者存在阳性手术切缘,这是 LR 的预后因素,而 DM 和 OS 则由肿瘤分级和大小预测。该大型患者队列的研究结果可能为 MFS 的新治疗方案提供基准。